NasdaqGS:BEAT

Stock Analysis Report

Executive Summary

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has BioTelemetry's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.1%

BEAT

-0.3%

US Healthcare

-0.6%

US Market


1 Year Return

-30.7%

BEAT

-9.2%

US Healthcare

0.7%

US Market

BEAT underperformed the Healthcare industry which returned -9.1% over the past year.

BEAT underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

BEATIndustryMarket
7 Day-2.1%-0.3%-0.6%
30 Day3.5%2.1%4.9%
90 Day-14.4%-0.8%1.7%
1 Year-30.7%-30.7%-7.8%-9.2%3.0%0.7%
3 Year124.7%124.7%29.7%24.4%44.8%35.4%
5 Year524.0%524.0%66.1%56.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is BioTelemetry's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

Should You Investigate BioTelemetry, Inc. (NASDAQ:BEAT) At US$39.65?

Valuation

Is BioTelemetry undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioTelemetry's share price is below the future cash flow value, and at a moderate discount (> 20%).

BioTelemetry's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

BioTelemetry is overvalued based on earnings compared to the US Healthcare industry average.

BioTelemetry is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

BioTelemetry is poor value based on expected growth next year.


Price Based on Value of Assets

BioTelemetry is overvalued based on assets compared to the US Healthcare industry average.


Next Steps

Future Growth

How is BioTelemetry expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

24.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioTelemetry's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).

BioTelemetry's earnings are expected to grow significantly at over 20% yearly.

BioTelemetry's revenue growth is expected to exceed the United States of America market average.

BioTelemetry's earnings growth is expected to exceed the United States of America market average.

BioTelemetry's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BioTelemetry will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has BioTelemetry performed over the past 5 years?

39.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioTelemetry has delivered over 20% year on year earnings growth in the past 5 years.

BioTelemetry has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

BioTelemetry has become profitable in the last year making it difficult to compare the US Healthcare industry average.


Return on Equity

BioTelemetry has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

BioTelemetry used its assets more efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

BioTelemetry's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is BioTelemetry's financial position?


Financial Position Analysis

BioTelemetry is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioTelemetry's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

BioTelemetry's level of debt (56.7%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (28.1% vs 56.7% today).

Debt is well covered by operating cash flow (47.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 7.2x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.7x debt.


Next Steps

Dividend

What is BioTelemetry's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioTelemetry's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioTelemetry's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioTelemetry has not reported any payouts.

Unable to verify if BioTelemetry's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioTelemetry has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioTelemetry's salary, the management and board of directors tenure and is there insider trading?

8.7yrs

Average management tenure


CEO

Joe Capper (55yo)

9.3yrs

Tenure

US$3,875,558

Compensation

Mr. Joseph H. Capper, also known as Joe, has been the Chief Executive Officer and President at BioTelemetry, Inc. formerly known as CardioNet, Inc. since June 2010. Mr. Capper served as the Chief Executive ...


CEO Compensation Analysis

Joe's remuneration is about average for companies of similar size in United States of America.

Joe's compensation has increased in line with BioTelemetry recently becoming profitable.


Management Age and Tenure

8.7yrs

Average Tenure

50yo

Average Age

The average tenure for the BioTelemetry management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

10.3yrs

Average Tenure

68yo

Average Age

The average tenure for the BioTelemetry board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Peter Kowey

    Medical Director and Chairman of Medical Advisory Board

    • Tenure: 10.5yrs
  • Joe Capper (55yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$3.88m
  • Peter Ferola (50yo)

    Senior VP

    • Tenure: 8.6yrs
    • Compensation: US$918.00k
  • Scott Satin

    President & General Manager of BioTel Research

    • Tenure: 0yrs
  • Andy Broadway (49yo)

    President of BioTel Heart

    • Tenure: 1.7yrs
    • Compensation: US$1.01m
  • Heather Getz (44yo)

    Executive VP & CFO

    • Tenure: 9.7yrs
    • Compensation: US$1.63m
  • Dan Wisniewski (55yo)

    Senior Vice President of Technical Operations

    • Tenure: 8.8yrs
    • Compensation: US$935.10k
  • Manish Wadhwa

    Chief Medical Officer

    • Tenure: 0.08yrs
  • Tim Raher

    Senior Vice President of Human Resources

    • Tenure: 2.2yrs

Board Members

  • Kirk Gorman (68yo)

    Chairman

    • Tenure: 7.9yrs
    • Compensation: US$230.66k
  • Rebecca Rimel (68yo)

    Director

    • Tenure: 10.3yrs
    • Compensation: US$205.03k
  • David Benditt (72yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Peter Kowey

    Medical Director and Chairman of Medical Advisory Board

    • Tenure: 10.5yrs
  • Joe Frick (66yo)

    Independent Director

    • Tenure: 5.9yrs
    • Compensation: US$201.93k
  • Joe Capper (55yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$3.88m
  • Robert Rubin (73yo)

    Director

    • Tenure: 12.2yrs
    • Compensation: US$199.42k
  • Arthur Moss

    Member of Medical Advisory Board

    • Tenure: 10.5yrs
  • Kenneth Ellenbogen

    Member of Medical Advisory Board

    • Tenure: 10.5yrs
  • Tony Conti (70yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$203.16k

Company Information

BioTelemetry, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioTelemetry, Inc.
  • Ticker: BEAT
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.425b
  • Shares outstanding: 33.89m
  • Website: https://www.gobio.com

Number of Employees


Location

  • BioTelemetry, Inc.
  • 1000 Cedar Hollow Road
  • Suite 102
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
C25DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2008
BEATNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2008
0HNHLSE (London Stock Exchange)YesCommon StockGBUSDMar 2008

Biography

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manuf ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:52
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.